Literature DB >> 8529706

Preventive and therapeutic AIDS peptide vaccines.

A Rubinstein1, S Cryz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8529706     DOI： 10.1007/bf02191502

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


× No keyword cloud information.
  10 in total

1.  Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.

Authors:  T J Palker; T J Matthews; A Langlois; M E Tanner; M E Martin; R M Scearce; J E Kim; J A Berzofsky; D P Bolognesi; B F Haynes
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

2.  Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles.

Authors:  G T Layton; S J Harris; A J Gearing; M Hill-Perkins; J S Cole; J C Griffiths; N R Burns; A J Kingsman; S E Adams
Journal:  J Immunol       Date:  1993-07-15       Impact factor: 5.422

3.  Cellular immune responses induced by in vivo priming with a lipid-conjugated multimeric antigen peptide.

Authors:  B Nardelli; J P Tam
Journal:  Immunology       Date:  1993-07       Impact factor: 7.397

4.  A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

Authors:  G Pialoux; J L Excler; Y Rivière; G Gonzalez-Canali; V Feuillie; P Coulaud; J C Gluckman; T J Matthews; B Meignier; M P Kieny
Journal:  AIDS Res Hum Retroviruses       Date:  1995-03       Impact factor: 2.205

5.  Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.

Authors:  B F Haynes; J V Torres; A J Langlois; D P Bolognesi; M B Gardner; T J Palker; R M Scearce; D M Jones; M A Moody; C McDanal
Journal:  J Immunol       Date:  1993-08-01       Impact factor: 5.422

Review 6.  NIH conference. HIV vaccine development: a progress report.

Authors:  D F Hoth; D P Bolognesi; L Corey; S H Vermund
Journal:  Ann Intern Med       Date:  1994-10-15       Impact factor: 25.391

7.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

Authors:  M D Daniel; F Kirchhoff; S C Czajak; P K Sehgal; R C Desrosiers
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

8.  Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

Authors:  T J Palker; M E Clark; A J Langlois; T J Matthews; K J Weinhold; R R Randall; D P Bolognesi; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

9.  A region of the third variable loop of HIV-1 gp120 is recognized by HLA-B7-restricted CTLs from two acute seroconversion patients.

Authors:  J T Safrit; A Y Lee; C A Andrews; R A Koup
Journal:  J Immunol       Date:  1994-10-15       Impact factor: 5.422

10.  Human immunodeficiency virus-1 principal neutralizing domain peptide-toxin A conjugate vaccine.

Authors:  S J Cryz; H Goldstein; M Pettoello-Mantovani; A Kim; E Fürer; J U Que; T Hasler; A Rubinstein
Journal:  Vaccine       Date:  1995-01       Impact factor: 4.169
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.